Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04712812 · ClinicalTrials.gov registry record
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
A clinical trial of Hereditary Spastic Paraplegia and SPG50, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 700
- Enrollment target
- 1
- Study location
NCT04712812: Recruiting study of Hereditary Spastic Paraplegia and SPG50, sponsored by Boston Children's Hospital.
NCT04712812 is a study of Hereditary Spastic Paraplegia and SPG50 that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 700 participants, above the 116-participant average among 5 other Hereditary Spastic Paraplegia trials with a reported enrollment target (503% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04712812, a study of Hereditary Spastic Paraplegia and SPG50, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male and female patients, under the age of 30, who exhibited early onset symptoms of HSP with (1) a clinical diagnosis of hereditary spastic paraplegia and (2) the presence of variants in HSP related genes and/or be a relative of a person with such a diagnosis. Currently, the treatment for this disorder is generally symptomatic and available therapies improve quality of life, but are grossly inefficient in slowing the disease progression. Access to the registry information will be limited to the study staff who are responsible for recruitment and maintenance of the registry. We hope that recruitment into the registry for studies will advance knowledge of the causes, clinical course, diagnosis, and treatment of these conditions.
Primary Outcome
Establish the disease spectrum through a cross-sectional analysis of clinical, imaging and molecular data
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2020-04-27 |
| Est. Completion | 2030-12-31 |
What NCT04712812 shows while recruiting
NCT04712812 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 116-participant average among 5 other Hereditary Spastic Paraplegia trials with a reported enrollment target (503% higher).
The record links to 10 conditions, with Hereditary Spastic Paraplegia appearing as the primary indexed condition, and to 0 interventions.
NCT04712812 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04712812 about?
NCT04712812 is a clinical study titled "Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia". The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male and female patients, under the age of 30, who exhibited early onset symptoms of HSP ...
What is the current status of trial NCT04712812?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2020-04-27. Estimated completion is 2030-12-31.
What conditions does trial NCT04712812 study?
This clinical trial studies the following conditions: Hereditary Spastic Paraplegia, SPG50, Early Onset Hereditary Spastic Paraplegia, SPG4, SPG47.
Who is sponsoring clinical trial NCT04712812?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04712812 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Spastic Paraplegia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Spastic Paraplegia - Centers of Excellence Research Network
RECRUITING
-
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
RECRUITING
-
Neuromodulation to Enhance Motor Function in HSP
RECRUITING · NA
-
Phenotype, Genotype and Biomarkers 2
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI